Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 1,718 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $155.19, for a total transaction of $266,616.42. Following the completion of the transaction, the chief marketing officer now owns 116,142 shares of the company’s stock, valued at $18,024,076.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Monday, October 2nd, Jeffrey Chodakewitz sold 3,437 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68.
  • On Wednesday, August 2nd, Jeffrey Chodakewitz sold 1,796 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.13, for a total transaction of $276,817.48.
  • On Thursday, August 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $154.17, for a total transaction of $830,976.30.
  • On Friday, July 21st, Jeffrey Chodakewitz sold 46,733 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $160.96, for a total transaction of $7,522,143.68.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.19% during trading on Wednesday, reaching $154.76. 1,050,665 shares of the company were exchanged. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $167.85. The stock has a market capitalization of $39.02 billion, a price-to-earnings ratio of 148.66 and a beta of 1.73. The company has a 50 day moving average price of $154.24 and a 200-day moving average price of $136.37.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million during the quarter, compared to analysts’ expectations of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2017/10/18/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-1718-shares-of-stock.html.

Several analysts recently commented on the stock. Royal Bank Of Canada raised their price target on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday. DA Davidson assumed coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price target for the company. BTIG Research assumed coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. They set a “buy” rating and a $200.00 price target for the company. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Wednesday, September 27th. Finally, Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price target for the company in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, five have given a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $167.25.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRTX. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after purchasing an additional 132 shares during the period. FNY Partners Fund LP lifted its stake in shares of Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after purchasing an additional 900 shares during the period. Dupont Capital Management Corp purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $186,000. State of Alaska Department of Revenue purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $197,000. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $203,000. Institutional investors own 92.82% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.